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EpiVax, Inc., a Rhode Island-based Biotechnology company, develops vaccines that exploit T cell immunity
using the innovative iVAX vaccine antigen design platform. The premise of our strategy is the crucial role T cells
play in development of protective antibody and cell-mediated immunity in natural infection. Because vaccines
aim to recapitulate protective immune responses in infection, a vaccine should effectively harness T cell
immunity to be protective. The significance of T cell immunity is underscored by COVID-19. Efficacy trial and
real-world COVID-19 vaccine data for different vaccine modalities show a single vaccine dose is as much as
90% effective starting 14 days post-administration, when 100% of vaccinees have functional CD4 and CD8 T
cells but no detectable neutralizing antibodies. As T cells support the SARS-CoV-2 antibody response, clear
virus-infected cells, and may be required to block transmission, we set out to develop a vaccine designed by
iVAX to enhance T cell immunity and provide long lasting protection.
Using the iVAX platform, we identified conserved peptide epitopes associated with SARS-CoV-2 T cell immunity
and assessed their immunogenicity in an HLA transgenic mouse model to support development of a T celldirected COVID-19 vaccine. SARS-CoV-2 spike, membrane and envelope sequences were analyzed for
potential binding to HLA class I and class II supertype alleles using EpiMatrix. JanusMatrix was used to identify
SARS-CoV-2 epitopes that share TCR-face conservation with epitopes restricted by the same alleles, but found
in the human proteome, and related alpha- and beta-coronaviruses. Conservation of epitopes with circulating
SARS-CoV-2 was assessed using the Epitope Content Comparison (EpiCC) algorithm and showed the vaccine
epitopes match >90% of the corresponding sequences in representative B.1.1.7, B.1.351, P.1, B.1.617.2, and
B.1.1.529 variants. Epitopes were assayed for antigenicity and 66% of 32 predicted epitopes were recognized in
direct ex vivo assays by individuals who mounted a protective immune response to SARS-CoV-2 infection. T
cell responses correlated with total spike-specific IgG and neutralizing antibody responses (p<0.01). Individuals
with no SARS-CoV-2 experience demonstrated ex vivo responses to only 9% of epitopes. However, following a
period of epitope-specific T cell expansion in culture, these individuals demonstrated robust T cell responses to
97% of SARS-CoV-2 epitopes, similar to convalescents. These data suggest that pre-existing immunity,
potentially to common cold coronaviruses, may contribute to natural immunity and enhance vaccine efficacy.
Intradermal immunization of HLA-DR3 transgenic mice with 20 candidate peptides co-formulated with poly-ICLC
demonstrated robust type 1 immunity skewing (>100-fold over type 2; p<0.05). This alleviates concern that the
vaccine may enhance respiratory disease commonly associated with Th2 responses. Taken together, this work
improves our understanding of natural vaccine-induced immunity and informs the development of our EPVCov19 vaccine.
Unlike currently available SARS-CoV-2 vaccines, EPV-Cov19 is being developed as a T cell-targeted vaccine
and it is fully synthetic, requiring no cell culture expression. EPV-Cov19 consists of 15 peptides with over 200 T
cell epitopes (CD8 and CD4) from SARS-CoV-2 spike and membrane proteins. In a planned Phase 1 trial, we
intend to show that the peptides selected by EpiVax can boost the immunity of individuals previously vaccinated.
In addition, EPV-Cov19 is versatile and can be formulated in peptide, RNA, DNA or viral-vectored formats. The
iVAX platform used to design EPV-Cov19 may advance the development of SARS-CoV-2 vaccines and is
adaptable to vaccine discovery against other infectious diseases.
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